Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma

The only currently validated treatment for advanced hepatocellular carcinoma (HCC) is sorafenib. However, sorafenib has been mainly studied in patients with HCC developed in cirrhotic liver. Chemotherapy might be more suitable for patients with HCC in non-cirrhotic liver. We report the case of a you...

Descripción completa

Detalles Bibliográficos
Autores principales: Gras, Pauline, Truant, Stéphanie, Boige, Valérie, Ladrat, Laure, Rougier, Philippe, Pruvot, François-René, Hebbar, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Published online: April, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364045/
https://www.ncbi.nlm.nih.gov/pubmed/22666208
http://dx.doi.org/10.1159/000338242
_version_ 1782234480525705216
author Gras, Pauline
Truant, Stéphanie
Boige, Valérie
Ladrat, Laure
Rougier, Philippe
Pruvot, François-René
Hebbar, Mohamed
author_facet Gras, Pauline
Truant, Stéphanie
Boige, Valérie
Ladrat, Laure
Rougier, Philippe
Pruvot, François-René
Hebbar, Mohamed
author_sort Gras, Pauline
collection PubMed
description The only currently validated treatment for advanced hepatocellular carcinoma (HCC) is sorafenib. However, sorafenib has been mainly studied in patients with HCC developed in cirrhotic liver. Chemotherapy might be more suitable for patients with HCC in non-cirrhotic liver. We report the case of a young woman with fibrolamellar HCC in a non-cirrhotic liver, with histologically proven metastatic ganglionary relapse after surgical resection of the primary tumour. Chemotherapy with gemcitabine and oxaliplatin (GEMOX regimen) achieved a complete response without relapse five years after discontinuation of chemotherapy. This exceptional case raises the question of clinical trials specifically designed for patients with HCC in non-cirrhotic liver.
format Online
Article
Text
id pubmed-3364045
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-33640452012-06-04 Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma Gras, Pauline Truant, Stéphanie Boige, Valérie Ladrat, Laure Rougier, Philippe Pruvot, François-René Hebbar, Mohamed Case Rep Oncol Published online: April, 2012 The only currently validated treatment for advanced hepatocellular carcinoma (HCC) is sorafenib. However, sorafenib has been mainly studied in patients with HCC developed in cirrhotic liver. Chemotherapy might be more suitable for patients with HCC in non-cirrhotic liver. We report the case of a young woman with fibrolamellar HCC in a non-cirrhotic liver, with histologically proven metastatic ganglionary relapse after surgical resection of the primary tumour. Chemotherapy with gemcitabine and oxaliplatin (GEMOX regimen) achieved a complete response without relapse five years after discontinuation of chemotherapy. This exceptional case raises the question of clinical trials specifically designed for patients with HCC in non-cirrhotic liver. S. Karger AG 2012-04-03 /pmc/articles/PMC3364045/ /pubmed/22666208 http://dx.doi.org/10.1159/000338242 Text en Copyright © 2012 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: April, 2012
Gras, Pauline
Truant, Stéphanie
Boige, Valérie
Ladrat, Laure
Rougier, Philippe
Pruvot, François-René
Hebbar, Mohamed
Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
title Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
title_full Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
title_fullStr Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
title_full_unstemmed Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
title_short Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
title_sort prolonged complete response after gemox chemotherapy in a patient with advanced fibrolamellar hepatocellular carcinoma
topic Published online: April, 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364045/
https://www.ncbi.nlm.nih.gov/pubmed/22666208
http://dx.doi.org/10.1159/000338242
work_keys_str_mv AT graspauline prolongedcompleteresponseaftergemoxchemotherapyinapatientwithadvancedfibrolamellarhepatocellularcarcinoma
AT truantstephanie prolongedcompleteresponseaftergemoxchemotherapyinapatientwithadvancedfibrolamellarhepatocellularcarcinoma
AT boigevalerie prolongedcompleteresponseaftergemoxchemotherapyinapatientwithadvancedfibrolamellarhepatocellularcarcinoma
AT ladratlaure prolongedcompleteresponseaftergemoxchemotherapyinapatientwithadvancedfibrolamellarhepatocellularcarcinoma
AT rougierphilippe prolongedcompleteresponseaftergemoxchemotherapyinapatientwithadvancedfibrolamellarhepatocellularcarcinoma
AT pruvotfrancoisrene prolongedcompleteresponseaftergemoxchemotherapyinapatientwithadvancedfibrolamellarhepatocellularcarcinoma
AT hebbarmohamed prolongedcompleteresponseaftergemoxchemotherapyinapatientwithadvancedfibrolamellarhepatocellularcarcinoma

Ejemplares similares